The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data

English version České info

Background:
Dihydroartemisinin-piperaquine (DP) is increasingly recommended for antimalarial treatment in many endemic countries; however, concerns have been raised over its potential under dosing in young children. We investigated the influence of different dosing schedules on DP's clinical efficacy.

Methods and Findings:
A systematic search of the literature was conducted to identify all studies published between 1960 and February 2013, in which patients were enrolled and treated with DP. Principal investigators were approached and invited to share individual patient data with the WorldWide Antimalarial Resistance Network (WWARN). Data were pooled using a standardised methodology. Univariable and multivariable risk factors for parasite recrudescence were identified using a Cox's regression model with shared frailty across the study sites. Twenty-four published and two unpublished studies (n = 7,072 patients) were included in the analysis. After correcting for reinfection by parasite genotyping, Kaplan–Meier survival estimates were 97.7% (95% CI 97.3%–98.1%) at day 42 and 97.2% (95% CI 96.7%–97.7%) at day 63. Overall 28.6% (979/3,429) of children aged 1 to 5 years received a total dose of piperaquine below 48 mg/kg (the lower limit recommended by WHO); this risk was 2.3–2.9-fold greater compared to that in the other age groups and was associated with reduced efficacy at day 63 (94.4% [95% CI 92.6%–96.2%], p<0.001). After adjusting for confounding factors, the mg/kg dose of piperaquine was found to be a significant predictor for recrudescence, the risk increasing by 13% (95% CI 5.0%–21%) for every 5 mg/kg decrease in dose; p = 0.002. In a multivariable model increasing the target minimum total dose of piperaquine in children aged 1 to 5 years old from 48 mg/kg to 59 mg/kg would halve the risk of treatment failure and cure at least 95% of patients; such an increment was not associated with gastrointestinal toxicity in the ten studies in which this could be assessed.

Conclusions:
DP demonstrates excellent efficacy in a wide range of transmission settings; however, treatment failure is associated with a lower dose of piperaquine, particularly in young children, suggesting potential for further dose optimisation.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. PLoS Med 10(12): e32767. doi:10.1371/journal.pmed.1001564
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001564

Souhrn

Zdroje

1. CarneiroI, Roca-FeltrerA, GriffinJT, SmithL, TannerM, et al. (2010) Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One 5: e8988 doi: 10.1371/journal.pone.0008988

2. PriceR, LuxemburgerC, van VugtM, NostenF, KhamA, et al. (1998) Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg 92: 207–211.

3. SinclairD, ZaniB, DoneganS, OlliaroP, GarnerP (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev CD007483.

4. WhiteNJ (2008) The role of anti-malarial drugs in eliminating malaria. Malar J 7 (Suppl 1) S8.

5. WHO (2010) Guidelines for the treatment of malaria, second edition. 2012. Available: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.

6. WHO (2012) World malaria report 2012. 2012. Available: http://www.who.int/malaria/publications/world_malaria_report_2012/wmr2012_full_report.pdf.

7. BarnesKI, WatkinsWM, WhiteNJ (2008) Antimalarial dosing regimens and drug resistance. Trends Parasitol 24: 127–134.

8. WhiteNJ, PongtavornpinyoW, MaudeRJ, SaralambaS, AguasR, et al. (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.

9. SinclairD, GogtayN, BrandF, OlliaroP (2011) Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev CD008492.

10. ZwangJ, AshleyEA, KaremaC, D'AlessandroU, SmithuisF, et al. (2009) Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4: e6358 doi:10.1371/journal.pone.0006358

11. BassatQ, MulengaM, TintoH, PiolaP, BorrmannS, et al. (2009) Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 4: e7871 doi:10.1371/journal.pone.0007871

12. Four Artemisinin-Based Combinations Study G (2011) A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119 doi:10.1371/journal.pmed.1001119

13. ValechaN, PhyoAP, MayxayM, NewtonPN, KrudsoodS, et al. (2010) An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 5: e11880 doi:10.1371/journal.pone.0011880

14. DavisTM, HungTY, SimIK, KarunajeewaHA, IlettKF (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65: 75–87.

15. TarningJ, ZongoI, SomeFA, RouambaN, ParikhS, et al. (2012) Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 91: 497–505.

16. WWARN (2013) Clinical trials review. Available: http://www.wwarn.org/resistance/malaria/literature/overview.

17. AdamI, SalahMT, EltahirHG, ElhassanAH, ElmardiKA, et al. (2010) Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol 104: 319–326.

18. ArinaitweE, SandisonTG, WanziraH, KakuruA, HomsyJ, et al. (2009) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49: 1629–1637.

19. AshleyEA, KrudsoodS, PhaiphunL, SrivilairitS, McGreadyR, et al. (2004) Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 190: 1773–1782.

20. AshleyEA, McGreadyR, HutagalungR, PhaiphunL, SlightT, et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425–432.

21. BorrmannS, SasiP, MwaiL, BashraheilM, AbdallahA, et al. (2011) Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 6: e26005 doi:10.1371/journal.pone.0026005

22. GrandeT, BernasconiA, ErhartA, GamboaD, CasapiaM, et al. (2007) A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One 2: e1101 doi:10.1371/journal.pone.0001101

23. HasugianAR, PurbaHL, KenangalemE, WuwungRM, EbsworthEP, et al. (2007) Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 44: 1067–1074.

24. JanssensB, van HerpM, GoubertL, ChanS, UongS, et al. (2007) A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Heal 12: 251–259.

25. KamyaMR, YekaA, BirwaH, LugemwaM, RwakimariJB, et al. (2007) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2: e20 doi:10.1371/journal.pctr.0020020

26. KaremaC, FanelloCI, van OvermeirC, van GeertruydenJP, van DorenW, et al. (2006) Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 100: 1105–1111.

27. KarunajeewaHA, MuellerI, SennM, LinE, LawI, et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545–2557.

28. MayxayM, ThongpraseuthV, KhanthavongM, LindegardhN, BarendsM, et al. (2006) An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). Trop Med Int Heal 11: 1157–1165.

29. MensPF, SawaP, van AmsterdamSM, VersteegI, OmarSA, et al. (2008) A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 7: 237.

30. RatcliffA, SiswantoroH, KenangalemE, MaristelaR, WuwungRM, et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757–765.

31. SawaP, ShekalagheSA, DrakeleyCJ, SutherlandCJ, MweresaCK, et al. (2013) Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 1637–1645.

32. SmithuisF, KyawMK, PheO, AyeKZ, HtetL, et al. (2006) Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367: 2075–2085.

33. SmithuisF, KyawMK, PheO, WinT, AungPP, et al. (2010) Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10: 673–681.

34. TranTH, NguyenTT, NguyenHP, BoniMF, NgoVT, et al. (2012) In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J 11: 355.

35. YavoW, FayeB, KueteT, DjohanV, OgaSA, et al. (2011) Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J 10: 198.

36. YekaA, DorseyG, KamyaMR, TalisunaA, LugemwaM, et al. (2008) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3: e2390 doi:10.1371/journal.pone.0002390

37. ZongoI, DorseyG, RouambaN, DokomajilarC, SereY, et al. (2007) Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45: 1453–1461.

38. WWARN (2012) Clinical Module: Data Management and Statistical Analysis Plan Version 1.2. Oxford. Available: http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf.

39. GethingPW, PatilAP, SmithDL, GuerraCA, ElyazarIR, et al. (2011) A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 10: 378.

40. WWARN (2012) Statistical Analysis Plan DHA-PQP Dose Impact Study Group. Version 1.9. Oxford. Available: http://www.wwarn.org/sites/default/files/DHA-PQPDoseImpactStudyGroupSAP.pdf.

41. LevinML (1953) The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 9: 531–541.

42. DondorpAM, NostenF, YiP, DasD, PhyoAP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467.

43. PhyoAP, NkhomaS, StepniewskaK, AshleyEA, NairS, et al. (2012) Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 1960–1966.

44. LeangR, BarretteA, BouthDM, MenardD, AbdurR, et al. (2013) Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57: 818–826.

45. PriceRN, HasugianAR, RatcliffA, SiswantoroH, PurbaHL, et al. (2007) Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 51: 4090–4097.

46. NacherM, CarraraVI, AshleyE, McGreadyR, HutagalungR, et al. (2004) Seasonal variation in hyperparasitaemia and gametocyte carriage in patients with Plasmodium falciparum malaria on the Thai-Burmese border. Trans R Soc Trop Med Hyg 98: 322–328.

47. WhiteNJ (2008) How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.

48. BarnesKI, LittleF, SmithPJ, EvansA, WatkinsWM, et al. (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582–596.

49. CreekDJ, BigiraV, McCormackS, ArinaitweE, WanziraH, et al. (2013) Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 207: 1646–1654.

50. MwesigwaJ, ParikhS, McGeeB, GermanP, DrysdaleT, et al. (2010) Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 54: 52–59.

51. SalmanS, Page-SharpM, BattyKT, KoseK, GriffinS, et al. (2012) Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 56: 3288–3297.

52. TranTH, DolecekC, PhamPM, NguyenTD, NguyenTT, et al. (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363: 18–22.

53. StepniewskaK, AshleyE, LeeSJ, AnsteyN, BarnesKI, et al. (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570–579.